SynthesisFrontiers in nutrition2025
Probiotics as technological innovations in psychiatric disorders: patents and research reviews.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mechanistic Study of Schisandrin B in Alleviating Anxiety-Like Behaviors in Rats via Enhancement of Hippocampal Synaptic Plasticity and Restoration of the Intestinal Barrier.Food science & nutrition · 2026Article
- Probiotic characterization and spore production optimization of Lysinibacillus sp. MK212927.Applied microbiology and biotechnology · 2026Article
- Boosting Food System Stability Through Technological Progress in Price and Supply Dynamics.Foods (Basel, Switzerland) · 2025Article
- Probiotics as Antioxidant Strategy for Managing Diabetes Mellitus and Its Complications.Antioxidants (Basel, Switzerland) · 2025Review
- A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics have shown promising results in treating anxiety and depression by modulating the gut-brain-microbiota axis using probiotics, which has motivated increasing commercial and academic interest in innovations and the probiotic market. This work explored innovation trends in the use of probiotics in the management of anxiety and depression, through a patent search performed in the Espacenet patent database. To expand the discussion, an additional search was performed on ClinicalTrials.gov and ScienceDirect. Recently probiotic innovations developed were deposited as pharmaceutical products (24.1%), functional foods (20.4%), or both (51.8%). Probiotic strains showed anxiolytic, antidepressant or both effects related to one or more mechanisms including modulation of neurotransmitters (61.1%), neuroendocrine mediators (35.2%) or neuroinflammation and oxidative stress (20.3%). The effects mainly were related to strains of the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.